Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)

QLT Inc.

Status and phase

Terminated

Phase 2

Conditions

Prostatic Hyperplasia

Treatments

Device: Transurethral drug delivery system

Device: Transurethral light delivery system

Drug: Lemuteporfin for injection

Study type

Interventional

Funder types

Industry

Identifiers

NCT00116571

BPH 003

Details and patient eligibility

About

The purpose of this study is to determine if transurethral photodynamic therapy with lemuteporfin has a therapeutic effect on lower urinary tract symptoms due to an enlarged prostate.

Photodynamic therapy (known as "PDT") is a treatment that uses light to make a drug work. This means the drug is "light-activated". Light-activated drugs do not work until a certain color of light shines on the drug. When the drug and the light combine, they react together to destroy tissue.

This study is investigating PDT with lemuteporfin as a possible treatment for an enlarged prostate. PDT with lemuteporfin may destroy overgrown prostate tissue and help urinary symptoms go back to normal.

Full description

This is a multi-center, randomized, sham-controlled, double-blind, dose-finding study in parallel groups of subjects with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). All subjects will receive a fixed dose of lemuteporfin injected transurethrally into the prostate followed by transurethral application of either one of three active light doses or a sham light dose. Subjects will be followed for safety and efficacy for a minimum of three months to a maximum of 12 months. The primary study endpoint will be the change from baseline in AUA SI score at three months.

Sex

Male

Ages

21+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Men 21 years of age and older.
Subjects with LUTS due to BPH with AUA SI scores of 13 and over and Qmax between 5 and 15 mL/sec.
Subjects with urethral treatment length of at least 25 mm.

Exclusion criteria